Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in this setting. To evaluate the utility of the hypoxia-activated prodrug evofosfamide (TH-302) in HNSCC, we established t...

Descripción completa

Detalles Bibliográficos
Autores principales: Harms, Julia K., Lee, Tet-Woo, Wang, Tao, Lai, Amy, Kee, Dennis, Chaplin, John M., McIvor, Nick P., Hunter, Francis W., Macann, Andrew M. J., Wilson, William R., Jamieson, Stephen M.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678517/
https://www.ncbi.nlm.nih.gov/pubmed/31337055
http://dx.doi.org/10.3390/cells8070717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678517/
https://www.ncbi.nlm.nih.gov/pubmed/31337055
http://dx.doi.org/10.3390/cells8070717

Ejemplares similares